Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Total Company Sales by Quarter
Total Company Sales — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Total Company Sales: 4.0% in Q2 2026, up 6.0 pts from a year earlier.
Latest, Q2 2026
4.0%
Period ended Jun 30, 2026
Change on a year earlier
+6.0 pts
-2.0% in Q2 2025
History
31 quarters
Since Q4 2017
Sources
31
Documents cited below
Where the Q2 2026 figure comes from
“|| TOTAL SALES (1) | $ | 16,286 | $ | 16,607 | $ | 32,893 | $ | 15,529 | $ | 15,806 | $ | 31,335 | $ | 17,276 | $ | 16,400 | $ | 65,011 | 5 | 4 | 5 | 3”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Table 3.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Total Company Sales (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-company-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.